Drug interactions in hospital prescriptions in Denmark: Prevalence and associations with adverse outcomes-Reference-Cited by-同舟云学术

Drug interactions in hospital prescriptions in Denmark: Prevalence and associations with adverse outcomes

Published:2022-02-22 Issue:6 Volume:31 Page:632-642
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiology and Drug

Author:

Leal Rodríguez Cristina¹^ORCID,Kaas‐Hansen Benjamin Skov¹²^ORCID,Eriksson Robert¹³^ORCID,Biel Jorge Hernansanz¹^ORCID,Belling Kirstine G.¹^ORCID,Andersen Stig Ejdrup²^ORCID,Brunak Søren¹^ORCID

Affiliation:

1. Novo Nordisk Foundation Center for Protein Research Faculty of Health and Medical Sciences, University of Copenhagen Copenhagen Denmark

2. Clinical Pharmacology Unit Zealand University Hospital Roskilde Denmark

3. Department of Pulmonary and Infectious Diseases Nordsjællands Hospital Hillerød Denmark

Funder

Innovationsfonden

Novo Nordisk Fonden

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.5415

Reference47 articles.

1. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010

2. Drug-Drug Interactions Related to Hospital Admissions in Older Adults: A Prospective Study of 1000 Patients

3. Potential drug–drug interactions in the medication of medical patients at hospital discharge

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characteristics of CYP3A4-related potential drug-drug interactions in outpatients receiving prescriptions from multiple clinical departments;Journal of Pharmaceutical Health Care and Sciences;2024-08-05

2. Survey of Potential Drug Interactions, Use of Non-Medical Health Products, and Immunization Status among Patients Receiving Targeted Therapies;Pharmaceuticals;2024-07-14

3. A characterization of patients with low soluble urokinase plasminogen activator receptor who died within 90 days of hospital discharge;Basic & Clinical Pharmacology & Toxicology;2024-07-11

4. Evidence-based pharmacotherapy in cardiology. National guideline;Rational Pharmacotherapy in Cardiology;2024-03-29

5. Avapritinib Carries the Risk of Drug Interaction via Inhibition of UDP-Glucuronyltransferase (UGT) 1A1;Current Drug Metabolism;2024-03